Health Capital Helsinki
  • Home
  • Why Helsinki Metropolitan
  • About us
  • News
  • Events
  • Opportunities
  • Careers
  • Contact
  • Search
  • Menu Menu
© Business Finland
Dec 17, 2020

First ever event to build bridges between investors and Finnish health research

The path from the table of a researcher to a marketable future medication, health care product, or health care solution is long and requires financial planning. Realized in cooperation by Business Finland, Business Finland Venture Capital, Finnish Industry Investment Ltd (Tesi), and Health Capital Helsinki, investor event Finnish Health and Life Science Research Showcase for Investors brought together international investors and Finnish future innovations in November 2020.

Aalto University

So far, foreign investments in Finnish health technology companies – in the field of health and life sciences, in particular – have been minor. There are no funds specializing in this field in Finland, which is why an international meeting was needed. Arranged in November, the virtual event Finnish Health and Life Science Research Showcase for Investors brought together 26 promising projects at the research stage from Finnish universities and 20 international and 17 Finnish investors. The event aimed at boosting the recognition of the Finnish projects, exposing the researchers to private investors, promoting awareness of available funding opportunities and attracting investors towards the projects that are still at the research stage.

There was a genuine need for such an event, because a strong capital base is required due to the long product development cycles of the industry. Understanding of public and private funding and the available opportunities assist in this process. For the second year in a row, Finland was Europe’s most active capital investment market when comparing the value of investments in euros to the GDP. Last year, Finnish startups combined attracted more than half a billion euros in investments, while the share of health and life sciences was around 10%.

“In the field of health care, Finnish venture capitalists are interested in digital health applications and start-ups, in particular,” says Joni Karsikas from Tesi. “There are more international investors, and they look at a broader picture of the sector. International funds that make large investments finance more advanced companies, while still keeping a keen eye on emerging companies.”

From the perspective of researchers, understanding the world of investing and practicing investment negotiations is important, because they will inevitably need capital. “The project is still at its early stages. We will have to start searching for funding in the near future,” says Ville Paavilainen from the University of Helsinki, who presented the project Smart ID at the event. “This was the first time we pitched our project to investors. We received highly valuable experience and understanding on how we need to revise our sales pitch.”

We received highly valuable experience and understanding on how we need to revise our sales pitch.

© Business Finland

“Knowing that there are investors with a potential interest in your project is hopefully a motivator to keep on going.”

For investors, meeting representatives of research projects is work focusing on the future, according to Soren Lemonius and Stephanie Munk from Sunstone Life Science Ventures: “Decisions on e.g. lead indication or licensing agreement made very early in investment opportunities may impact the quality of the opportunity and thus Sunstone’s interest. It is in our own interest to try to provide some guidance as early as possible. Being an entrepreneur is an uncertain venture with many bumpy roads – knowing that there are investors with a potential interest in your project is hopefully a motivator to keep on going – even when it is difficult and the academic career seems safer and more attractive.”

Rishabh Chawla from V-Bio Ventures believes in getting in contact at an early stage: “V-Bio being an early-stage investor is always looking for new and exciting investment opportunities coming out of European universities. Events like this showcase not only help us to identify such opportunities but also help initiate the first dialogue with the research groups. We have already contacted several research groups after the event.”

“Research groups should start a dialogue with us when they have significant in-vivo proof of principal data and have initial ideas about the disease indication they want pursue”, Chawla hints.

Additional information:

Lauri Kuronen

Lauri Kuronen

Senior Business Advisor

Health Capital Helsinki
lauri.kuronen (at) healthcapitalhelsinki.fi
+358 40 575 1847

Health Capital Helsinki

PS. Don’t forget the Dealflow portal! It is a digital platform offered by Business Finland for investors and companies seeking for investors.

 
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn

Latest news

Health Capital Helsinki

People walking into Messukeskus for HIMSS22 Europe eventArd Jongsma/Still Words Photography

Helsinki health ecosystem highlighted in European media

Jul 1, 2022
Read more
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/07/220615HIMSSEurope20220013_resize.jpg 1057 2048 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-07-01 11:24:282022-07-01 11:25:41Helsinki health ecosystem highlighted in European media
Crowd at HIMSS Europe 2019 in HelsinkiArd Jongsma / Still Words Photography

See you at HIMSS22 Europe! The Finnish Pavilion program out now

Jun 2, 2022
Read more
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/05/190613HIMSSEuropeConferenceHelsinki20190065_resize.jpg 1046 1569 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-06-02 09:00:222022-06-21 11:05:27See you at HIMSS22 Europe! The Finnish Pavilion program out now
Close up of an eye behind protective glassesBusiness Finland

Investor event on 19 May: How to invest in Health & Life Sciences – Practical insights and examples

Apr 25, 2022
Read more
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/04/kuva-res150-flipped.jpg 1125 2000 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-04-25 09:00:312022-05-19 14:19:40Investor event on 19 May: How to invest in Health & Life Sciences – Practical insights and examples
All news

Health Capital Helsinki

Helsinki Partners
Kasarmikatu 36
00130 HELSINKI
FINLAND

Privacy notice

Sign up to our newsletter

Subscribe

Follow us

  • twitter
  • linkedin
Health Capital Helsinki

We use cookies to give you the best experience on our website.

Find out more and set your preferences settings.

Powered by  GDPR Cookie Compliance
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential website cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.

We also use Twitter's and LinkedIn's cookies to help us improve our content and reach.

Please enable essential website cookies first so that we can save your preferences!

Privacy notice

You can read about how we use your data on our Privacy notice page.

Privacy notice

Scroll to top